Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Repatha (evolocumab)
pCPA File Number:
21004
Negotiation Status:
Concluded without agreement
Indication(s):
Primary hyperlipidemia and mixed dyslipidemia
Sponsor/Manufacturer:
Amgen Canada Inc.
CADTH Project Number:
SR0515-000
pCPA Engagement Letter Issued:
2018-08-08
Negotiation Process Concluded:
2019-07-25